Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Conference Correspondent  - ESMO Highlights

Cytoreductive surgery and platinum-based chemotherapy are the standard of care for patients with newly diagnosed advanced ovarian cancer.1 However, approximately 75% of patients who have an initial response subsequently have a recurrence of their cancer, which is rarely curable.2 Here, Moore and colleagues present data from SOLO1, the first phase 3 trial in which patients with BRCA mutations and newly diagnosed advanced ovarian cancer received the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib as maintenance therapy after platinum-based chemotherapy.3

In this randomized, controlled, double-blind trial, eligible patients had newly diagnosed, International Federation of Gynecology and Obstetrics stage III to IV, high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer; had received platinum-based chemotherapy; and were in clinical complete or partial response. Patients were randomized 2:1 to receive either 300-mg olaparib tablets twice daily or placebo. The primary end point was investigator-assessed progression-free survival (PFS) by modified Response Evaluation Criteria in Solid Tumors v1.1, with secondary end points including PFS, overall survival (OS), time from randomization to first subsequent therapy or death, and health-related quality of life using the Functional Assessment of Cancer Therapy-Ovarian Cancer score.

Of 391 randomized patients, 260 received olaparib and 131 received placebo. Baseline characteristics were well-balanced between the groups, and the median follow-up was 41 months. Patients received treatment for 2 years if there was no evidence of disease. Investigator-assessed PFS showed a significant 70% reduction in the risk for progression or death with olaparib versus placebo (hazard ratio [HR], 0.30; 95% confidence interval [CI], 0.23-0.41; P <.0001), which was similar to that of blinded independent central review (HR, 0.28; 95% CI, 0.20-0.39; P <.0001). Median time to first subsequent therapy or death was significantly longer for the olaparib group (between-group difference, 36.7 months; HR, 0.30; 95% CI, 0.22-0.40; P <.0001), as was the median time from randomization to second progression or death (between-group difference not calculable; HR, 0.50; 95% CI, 0.35-0.72; P <.0002). OS data are immature.

Adverse events in SOLO1 were mostly low grade. The most common high-grade (≥grade 3) toxicities associated with olaparib were anemia (22%) and neutropenia (8%). Olaparib dose reductions, interruptions, and discontinuations occurred in 28%, 52%, and 12%, respectively. No significant change from baseline in health-related quality of life scores with olaparib was observed.

These data are the first to show that maintenance olaparib leads to a substantial, unprecedented improvement in PFS in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation, with a difference of approximately 3 years in median PFS for olaparib versus placebo. There was also a statistically significant improvement with olaparib over placebo in time from randomization to a second progression event, suggesting that olaparib did not diminish patients’ ability to benefit from subsequent therapy. Olaparib was generally well-tolerated, with a safety profile consistent with that observed in the relapsed disease setting.

References

  1. Matulonis UA. Clin Adv Hematol Oncol. 2018;16(6):426-437.
  2. Hoppenot C, et al. Gynecol Oncol. 2018;148(1):204-212.
  3. Moore KN, et al. ESMO 2018. Abstract LBA7.
Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.